[go: up one dir, main page]

IN2012DN00551A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00551A
IN2012DN00551A IN551DEN2012A IN2012DN00551A IN 2012DN00551 A IN2012DN00551 A IN 2012DN00551A IN 551DEN2012 A IN551DEN2012 A IN 551DEN2012A IN 2012DN00551 A IN2012DN00551 A IN 2012DN00551A
Authority
IN
India
Prior art keywords
radioimmunoconjugate
relates
methods
radioimmvmoconjugate
hum195
Prior art date
Application number
Other languages
English (en)
Inventor
Simon Jaime
Gaylord King A
Manuel Moreno Bermudez Josue
Original Assignee
Actinium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actinium Pharmaceuticals Inc filed Critical Actinium Pharmaceuticals Inc
Publication of IN2012DN00551A publication Critical patent/IN2012DN00551A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN551DEN2012 2009-07-22 2010-07-22 IN2012DN00551A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22771009P 2009-07-22 2009-07-22
PCT/US2010/042885 WO2011011592A1 (fr) 2009-07-22 2010-07-22 Procédés de génération de radioimmunoconjugués

Publications (1)

Publication Number Publication Date
IN2012DN00551A true IN2012DN00551A (fr) 2015-06-12

Family

ID=43499411

Family Applications (1)

Application Number Title Priority Date Filing Date
IN551DEN2012 IN2012DN00551A (fr) 2009-07-22 2010-07-22

Country Status (8)

Country Link
US (1) US9603954B2 (fr)
EP (1) EP2456472B1 (fr)
JP (2) JP5985392B2 (fr)
CN (2) CN102596258B (fr)
CA (1) CA2768658C (fr)
IN (1) IN2012DN00551A (fr)
RU (2) RU2565402C2 (fr)
WO (1) WO2011011592A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201208309D0 (en) * 2012-05-11 2012-06-27 Algeta As Complexes
US20150157742A1 (en) * 2013-12-11 2015-06-11 The European Atomic Energy Community (Euratom), Represented By The European Commission SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225
EP3142710A4 (fr) * 2014-05-16 2018-04-25 Memorial Sloan Kettering Cancer Center Marquage en une étape par actinium-225 d'anticorps pour obtenir une haute activité spécifique
US11149059B2 (en) * 2015-09-08 2021-10-19 Waters Technologies Corporation Multidimensional chromatography method for analysis of antibody-drug conjugates
US11896683B2 (en) 2016-12-16 2024-02-13 The Australian National University Radiolabelled material for targeted administration
ES2960030T3 (es) 2017-01-12 2024-02-29 Radiomedix Inc Tratamiento de células cancerosas que sobreexpresan receptores de somatostatina utilizando derivados de ocreótido quelados con radioisótopos
EP4592320A3 (fr) * 2017-07-31 2025-09-24 Actinium Pharmaceuticals, Inc. Traitements pour une malignité hématologique
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
US20230390424A1 (en) * 2020-09-11 2023-12-07 Actinium Pharmaceuticals, Inc. Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers
US12447218B1 (en) * 2021-02-09 2025-10-21 Actinium Pharmaceuticals, Inc. Radioconjugates directed to MHC-complexed antigens in cancer
EP4490197A2 (fr) 2022-03-24 2025-01-15 Actinium Pharmaceuticals, Inc. Anticorps anti-cd45 humanisés
CA3252793A1 (fr) 2022-03-30 2025-07-07 Nihon Medi-Physics Co., Ltd. Procédé de production de complexe
CA3258344A1 (fr) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Chélateurs et conjugués bifonctionnels
CN120225566A (zh) 2022-08-22 2025-06-27 雅博得乐医疗公司 Dll3结合分子及其用途
US20250388688A1 (en) 2024-04-04 2025-12-25 Ethyreal Bio, Inc. Anti-tshr antibodies and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001387A (en) 1973-07-30 1977-01-04 Medi-Physics, Inc. Process for preparing radiopharmaceuticals
US4305922A (en) 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4296785A (en) 1979-07-09 1981-10-27 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4732864A (en) 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4894364A (en) 1983-10-26 1990-01-16 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4663129A (en) 1985-01-30 1987-05-05 The United States Of America As Represented By The United States Department Of Energy Isotopic generator for bismuth-212 and lead-212 from radium
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5306509A (en) 1987-03-17 1994-04-26 Turner Robert E Prevention and treatment of oral lesions
IL87405A0 (en) 1987-08-12 1989-01-31 Immunomedics Inc Radiolabeled agents and methods and kits for the production thereof
US4833329A (en) 1987-11-20 1989-05-23 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US5612016A (en) * 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
US4923985A (en) 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
DE68925904T2 (de) 1988-05-25 1996-10-31 The United States Of America, Represented By The Secretary, U.S. Department Of Commerce, Springfield, Va. Makrocyclische chelate und verwendungsverfahren
US5292868A (en) 1989-05-26 1994-03-08 Akzo N.V. Chelating agents for attaching metal ions to proteins
ES2053196T3 (es) 1989-06-19 1994-07-16 Akzo Nv Metodo para la produccion de un radioinmunoconjugado.
JP3194433B2 (ja) 1989-07-12 2001-07-30 マリンクロッド・インコーポレイテッド 放射線診断用気体放射性核種の製造方法および放射線診断用気体放射性核種の製造装置
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
LU87684A1 (de) 1990-02-23 1991-10-08 Euratom Verfahren zur erzeugung von aktinium-225 und wismut-213
US5038046A (en) 1990-07-10 1991-08-06 Biotechnetics Method and generator for producing radioactive lead-212
US6403771B1 (en) 1991-02-19 2002-06-11 Actinium Pharmaceuticals, Limited Method and means for site directed therapy
CA2100709C (fr) 1992-07-27 2004-03-16 Maurits W. Geerlings Methode et moyens pour une therapie ciblee
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
CA2328528C (fr) 1998-05-20 2009-07-21 Immunomedics, Inc. Medicament renfermant un anticorps bispecifique antipathogene/anti-chaine invariante de la classe ii du systeme hla
DE69937797D1 (de) * 1998-05-26 2008-01-31 Sloan Kettering Inst Cancer Alpha-emittierende konstrukte sowie deren verwendung
CA2690395C (fr) 1998-06-22 2013-11-05 Immunomedics, Inc. Utilisation d'anticorps bi-specifiques pour diagnostic et therapie de pre-ciblage
CA2422291C (fr) * 2000-09-15 2011-03-08 Sloan-Kettering Institute For Cancer Research Therapie par particules alpha ciblees utilisant des conjugues d'actinium-225
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
WO2002080987A1 (fr) * 2001-04-09 2002-10-17 Progenics Pharmaceuticals, Inc. Immunotoxines anti-cd19
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
IL162201A0 (en) * 2002-01-03 2005-11-20 Schering Ag New methods for diagnosis and treatment of tumours
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
US20060058218A1 (en) * 2004-09-10 2006-03-16 General Electric Company Solid phase conjugation of complexing agents and targeting moieties
US7736647B2 (en) * 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
CA2650953A1 (fr) * 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combinaison d'un anticorps l19-sip anti domaine ed-b de la fibronectine et d'un anticorps anti-egfr

Also Published As

Publication number Publication date
EP2456472A4 (fr) 2014-08-27
CN102596258A (zh) 2012-07-18
JP2016199583A (ja) 2016-12-01
CN104710504B (zh) 2019-09-13
RU2704802C2 (ru) 2019-10-31
CN104710504A (zh) 2015-06-17
EP2456472A1 (fr) 2012-05-30
WO2011011592A1 (fr) 2011-01-27
CA2768658C (fr) 2018-04-03
EP2456472C0 (fr) 2024-03-27
EP2456472B1 (fr) 2024-03-27
JP5985392B2 (ja) 2016-09-06
RU2015137512A (ru) 2018-12-25
CN102596258B (zh) 2015-01-28
CA2768658A1 (fr) 2011-01-27
US20120220754A1 (en) 2012-08-30
HK1211304A1 (en) 2016-05-20
RU2565402C2 (ru) 2015-10-20
RU2012106301A (ru) 2013-08-27
JP2013500258A (ja) 2013-01-07
RU2015137512A3 (fr) 2019-04-02
US9603954B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
IN2012DN00551A (fr)
UA101487C2 (en) Humanized b-ly1 antibody formulation
NZ621170A (en) Anti-human cd52 immunoglobulins
IL206639A0 (en) Humanized anti-human nkg2a monoclonal antibody
SG178886A1 (en) Humanized anti-cdcp1 antibodies
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
IL245274B (en) Monoclonal antibodies against the 2her epitope
IL202232A (en) A method of making a human antibody derived from a rabbit parent antibody that binds to a desired antigen as well as a human antibody or fragment thereof produced by this method
EP4477668A3 (fr) Protéines contenant des anticorps fc hétérodimères et leurs procédés de production
HUE037095T2 (hu) Eljárások és reagensek monoklonális ellenanyagok elõállítására
IL222359A0 (en) Monoclonal antibodies against her2 antigens, and uses therefor
GB201108236D0 (en) Method
EP2331579A4 (fr) Anticorps monoclonaux
WO2010046775A3 (fr) Procédés pour produire des anticorps à partir de plasmocytes
WO2009128963A3 (fr) Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
PH12014501758A1 (en) Cd47 antibodies and methods of use thereof
AP2012006262A0 (en) Monoclonal antibodies to progastrin and their uses.
SG10201601279SA (en) Monoclonal Antibody STRO-4
DK3059337T3 (da) Adaptive immunity profiling og metoder til frembringelse af monoklonale antibodier
IL217000A0 (en) Readily isolated bispecific antibodies with native immunoglobulin format
IL193871A0 (en) Humanized anti-cd20 monoclonal antibody
NZ616382A (en) Antibodies specific to cadherin-17
WO2010042562A3 (fr) Anticorps du muc1*
AP2010005332A0 (en) Humanized antibodies specific for von willebrand factor.
MY182178A (en) Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration